As one of the most significant gatherings of oncology professionals worldwide, the 2024 ASCO (American Society of Clinical Oncology) Annual Meeting was held from May 31 to June 4 in Chicago, the United States, featuring over 200 sessions across the spectrum of disease.
Among 21 Oral presentations from China during the ASCO 2024, a study for non-small cell lung cancer (NSCLC) was presented by Prof. Fan Yun of Zhejiang Cancer Hospital (ZJCH).
For the treatment of NSCLC, Prof. Fan’s study: High-dose almonertinib in treatment-naïve EGFR-mutated NSCLC with CNS metastases: Efficacy and biomarker analysis were presented in the Central Nervous System Tumors Session, providing new therapeutic strategies and efficacy predictive biomarkers for patients with EGFR-mutated NSCLC with CNS metastases at baseline.
Prof. Fan Yun has long focused on the precision diagnosis and treatment of thoracic malignant tumors, as well as the mechanism and individualized treatment of central nervous system metastasis of malignant tumors. Prof. Fan has published over 50 papers in decent international journals including Lancet Respir Med, J Thorac Oncol, Clin Cancer Res, and Mol Oncol, and participated in multiple international cancer conferences such as ESMO, WCLC, and ELCC.
In addition, 6 studies from ZJCH were selected as poster presentations.
The discussions and exchanges in top conferences fully demonstrated the international influence in the cancer treatment of ZJCH. These studies have not only revolutionized cancer treatment practices in China but have also sparked significant progress worldwide.